Mitiglinide

Mitiglinide

SCHEMBL4457950

O=C(O)[C@@H](CC(=O)N1CC2CCCCC2C1)Cc1ccccc1

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABCC8KCNJ11

The experimentally established mechanism targets of Mitiglinide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CPA1 P15085 7/20 0.53
CPA3 P15088 3/20 0.53
CPB1 P15086 1/20 0.53
CPB2 Q96IY4 1/20 0.53
CYP1A2 P05177 1/20 0.50
MME P08473 1/20 0.47
FOLH1 Q04609 2/20 0.45
BCL2L1 Q07817 1/20 0.44
MCL1 Q07820 1/20 0.44
SLC1A3 P43003 1/20 0.42
SLC1A2 P43004 1/20 0.42
SLC1A1 P43005 1/20 0.42
LTA4H P09960 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mitiglinide SCHEMBL876930 1.00 CPA1 (0.53) CPA1CPA3CPB1CPB2CYP1A2
Mitiglinide SCHEMBL2864873 1.00 CPA1 (0.53) CPA1CPA3CPB1CPB2CYP1A2
Mitiglinide SCHEMBL49085 1.00 CPA1 (0.53) CPA1CPA3CPB1CPB2CYP1A2
Mitiglinide SCHEMBL676865 1.00 CPA1 (0.53) CPA1CPA3CPB1CPB2CYP1A2
Mitiglinide SCHEMBL9049521 1.00 CPA1 (0.53) CPA1CPA3CPB1CPB2CYP1A2
Mitiglinide SCHEMBL4457953 1.00 CPA1 (0.53) CPA1CPA3CPB1CPB2CYP1A2
Mitiglinide SCHEMBL6135224 0.99 CPA1 (0.51) CPA1CPA3CPB1CPB2CYP1A2
Mitiglinide SCHEMBL305840 0.99 CPA1 (0.51) CPA1CPA3CPB1CPB2CYP1A2
Mitiglinide SCHEMBL9047711 0.99 CPA1 (0.51) CPA1CPA3CPB1CPB2CYP1A2
Mitiglinide SCHEMBL9047718 0.99 CPA1 (0.51) CPA1CPA3CPB1CPB2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0507534-B1 Succinic acid compounds KISSEI PHARMACEUTICAL (JP) 1996-02-28 EP claimed
EP-1931359-A4 COMBINATION THERAPY FOR CONTROLLED CARBOHYDRATE DIGESTION ELIXIR PHARMACEUTICALS INC (US) 2009-04-01 EP disclosed
EP-1931359-A2 COMBINATION THERAPY FOR CONTROLLED CARBOHYDRATE DIGESTION Elixir Pharmaceuticals, Inc. (US) 2008-06-18 EP disclosed
WO-2007033292-A2 COMBINATION THERAPY FOR CONTROLLED CARBOHYDRATE DIGESTION ELIXIR PHARMACEUTICALS, INC. (US) 2007-03-22 WO disclosed
EP-0507534-B1 Succinic acid compounds KISSEI PHARMACEUTICAL (JP) 1996-02-28 EP disclosed
US-5202335-A Hypoglycemic, antidiabetic agents KISSEI PHARMACEUTICAL CO., LTD. (JP) 1993-04-13 US disclosed
EP-0507534-A1 Succinic acid compounds KISSEI PHARMACEUTICAL CO., LTD. (JP) 1992-10-07 EP disclosed